Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD
April 09, 2024 07:00 ET
|
Artios Pharma, Inc.
CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug...
Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer
February 07, 2024 08:00 ET
|
Artios Pharma, Inc.
CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug...
Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023
October 23, 2023 08:00 ET
|
Artios Pharma, Inc.
Molecular and clinical responses observed across multiple cancer types, including those with high replication stress Predictable and manageable safety profile with reliable pharmacokinetics offers...
Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023
October 05, 2023 08:00 ET
|
Artios Pharma, Inc.
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replication stress tumors Phase 1 dose escalation data...
Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer
February 09, 2023 08:00 ET
|
Artios Pharma, Inc.
ART0380 demonstrated a tolerable and manageable safety profile, with monotherapy clinical activity in tumors predicted to be sensitive to ATR inhibition in Phase 1 dose escalationFirst of three Phase...
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
August 10, 2022 03:00 ET
|
Artios Pharma, Inc.
ART4215 is a potentially first-in-class, highly selective, oral small molecule inhibitor targeting the Polθ polymerase domainInterim Phase 1 tolerability and pharmacokinetic data supports a...
Artios Appoints Samantha Truex to Board of Directors
June 23, 2022 08:00 ET
|
Artios Pharma, Inc.
CAMBRIDGE, United Kingdom and NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development of novel small molecule...
Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation
April 05, 2022 03:00 ET
|
Artios Pharma, Inc.
Phase 1a dose escalation of ART0380 defined initial regimen to be evaluated in Phase 1b setting.Phase 1a dose escalation demonstrated a predictable safety profile and no unexpected safety findings...
Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair
November 16, 2021 03:00 ET
|
Artios Pharma, Inc.
CAMBRIDGE, United Kingdom and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics...
Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215
September 28, 2021 03:00 ET
|
Artios Pharma, Inc.
Polθ inhibitor, ART4215, is the first selective, orally bioavailable, small molecule inhibitor of the Polθ polymerase domain to enter the clinicPhase 1/2a study evaluating Polθ inhibitor, ART4215, in...